449 related articles for article (PubMed ID: 32591969)
1. Poor Drug Sustainability in Inflammatory Bowel Disease Patients in Clinical Remission on Thiopurine Monotherapy.
Balram B; Lubov J; Theoret Y; Afif W; Bitton A; Wild G; Lakatos PL; Bessissow T
Dig Dis Sci; 2021 May; 66(5):1650-1657. PubMed ID: 32591969
[TBL] [Abstract][Full Text] [Related]
2. Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource.
Stournaras E; Qian W; Pappas A; Hong YY; Shawky R; ; Raine T; Parkes M;
Gut; 2021 Apr; 70(4):677-686. PubMed ID: 33004550
[TBL] [Abstract][Full Text] [Related]
3. Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients.
Kennedy NA; Kalla R; Warner B; Gambles CJ; Musy R; Reynolds S; Dattani R; Nayee H; Felwick R; Harris R; Marriott S; Senanayake SM; Lamb CA; Al-Hilou H; Gaya DR; Irving PM; Mansfield J; Parkes M; Ahmad T; Cummings JR; Arnott ID; Satsangi J; Lobo AJ; Smith M; Lindsay JO; Lees CW
Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1313-23. PubMed ID: 25284134
[TBL] [Abstract][Full Text] [Related]
4. 6-Mercaptopurine for Azathioprine Intolerant Inflammatory Bowel Disease: Literature Search and Reappraisal of Own Data.
Actis GC; Pellicano R; Rosina F
Inflamm Allergy Drug Targets; 2015; 14(2):133-7. PubMed ID: 26728773
[TBL] [Abstract][Full Text] [Related]
5. Routine use of thiopurines in maintaining remission in pediatric Crohn's disease.
Boyle BM; Kappelman MD; Colletti RB; Baldassano RN; Milov DE; Crandall WV
World J Gastroenterol; 2014 Jul; 20(27):9185-90. PubMed ID: 25083093
[TBL] [Abstract][Full Text] [Related]
6. Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases.
Yarur AJ; Gondal B; Hirsch A; Christensen B; Cohen RD; Rubin DT
J Clin Gastroenterol; 2018 Jul; 52(6):537-544. PubMed ID: 28723860
[TBL] [Abstract][Full Text] [Related]
7. Relapse rates after withdrawal of thiopurines in patients with inflammatory bowel disease.
Ranjan MK; Vuyyuru SK; Kante B; Kumar P; Mundhra SK; Golla R; Sharma R; Sahni P; Das P; Makharia G; Kedia S; Ahuja V
Int J Colorectal Dis; 2022 Aug; 37(8):1817-1826. PubMed ID: 35835862
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Thiopurine Treatment Failure in Biologic-Naïve Ulcerative Colitis Patients.
Thapa SD; Hadid H; Usman M; Imam W; Hassan A; Schairer J; Jafri SM; Kaur N
Dig Dis Sci; 2016 Jan; 61(1):230-7. PubMed ID: 26511478
[TBL] [Abstract][Full Text] [Related]
9. Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary.
Hanauer SB; Sandborn WJ; Lichtenstein GR
Gastroenterology; 2019 Jan; 156(1):36-42. PubMed ID: 30195449
[TBL] [Abstract][Full Text] [Related]
10. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
Coenen MJ; de Jong DJ; van Marrewijk CJ; Derijks LJ; Vermeulen SH; Wong DR; Klungel OH; Verbeek AL; Hooymans PM; Peters WH; te Morsche RH; Newman WG; Scheffer H; Guchelaar HJ; Franke B;
Gastroenterology; 2015 Oct; 149(4):907-17.e7. PubMed ID: 26072396
[TBL] [Abstract][Full Text] [Related]
11. Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse.
Iborra M; Herreras J; Boscá-Watts MM; Cortés X; Trejo G; Cerrillo E; Hervás D; Mínguez M; Beltrán B; Nos P
Dig Dis Sci; 2019 Jun; 64(6):1612-1621. PubMed ID: 30604371
[TBL] [Abstract][Full Text] [Related]
12. Minimal risk of lymphoma and non-melanoma skin cancer despite long-term use of thiopurines in patients with inflammatory bowel disease: A longitudinal cohort analysis from northern India.
Ranjan MK; Kante B; Vuyyuru SK; Kumar P; Mundhra SK; Golla R; Sharma R; Sahni P; Das P; Makharia G; Kedia S; Ahuja V
J Gastroenterol Hepatol; 2022 Aug; 37(8):1544-1553. PubMed ID: 35501287
[TBL] [Abstract][Full Text] [Related]
13. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
Holmstrøm RB; Mogensen DV; Brynskov J; Ainsworth MA; Nersting J; Schmiegelow K; Steenholdt C
Dig Dis Sci; 2018 Jun; 63(6):1583-1591. PubMed ID: 29564674
[TBL] [Abstract][Full Text] [Related]
14. Do Thiopurines Reduce the Risk of Surgery in Elderly Onset Inflammatory Bowel Disease? A 20-Year National Population-Based Cohort Study.
Alexakis C; Saxena S; Chhaya V; Cecil E; Curcin V; Pollok R
Inflamm Bowel Dis; 2017 Apr; 23(4):672-680. PubMed ID: 28151735
[TBL] [Abstract][Full Text] [Related]
15. Long-term effect of NUDT15 R139C on hematologic indices in inflammatory bowel disease patients treated with thiopurine.
Akiyama S; Matsuoka K; Fukuda K; Hamada S; Shimizu M; Nanki K; Mizuno S; Kiyohara H; Arai M; Sugimoto S; Iwao Y; Ogata H; Hisamatsu T; Naganuma M; Motobayashi M; Suzuki K; Takenaka K; Fujii T; Saito E; Nagahori M; Ohtsuka K; Mochizuki M; Watanabe M; Hashiguchi M; Kanai T
J Gastroenterol Hepatol; 2019 Oct; 34(10):1751-1757. PubMed ID: 31045285
[TBL] [Abstract][Full Text] [Related]
16. Thiopurine-induced pancreatitis in inflammatory bowel diseases.
Ledder O; Lemberg DA; Day AS
Expert Rev Gastroenterol Hepatol; 2015 Apr; 9(4):399-403. PubMed ID: 25494551
[TBL] [Abstract][Full Text] [Related]
17. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
Jahnsen J; Detlie TE; Vatn S; Ricanek P
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
[TBL] [Abstract][Full Text] [Related]
18. Outcome of concomitant treatment with thiopurines and allopurinol in patients with inflammatory bowel disease: A nationwide Danish cohort study.
Thomsen SB; Allin KH; Burisch J; Jensen CB; Hansen S; Gluud LL; Theede K; Kiszka-Kanowitz M; Nielsen AM; Jess T
United European Gastroenterol J; 2020 Feb; 8(1):68-76. PubMed ID: 32213059
[TBL] [Abstract][Full Text] [Related]
19. Thiopurines in inflammatory bowel disease revisited.
Bär F; Sina C; Fellermann K
World J Gastroenterol; 2013 Mar; 19(11):1699-706. PubMed ID: 23555158
[TBL] [Abstract][Full Text] [Related]
20. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.
Chaparro M; Garre A; Ricart E; Iborra M; Mesonero F; Vera I; Riestra S; García-Sánchez V; Luisa De Castro M; Martin-Cardona A; Aldeguer X; Mínguez M; de-Acosta MB; Rivero M; Muñoz F; Andreu M; Bargalló A; González-Muñoza C; Pérez Calle JL; García-Sepulcre MF; Bermejo F; Huguet JM; Cabriada JL; Gutiérrez A; Mañosa M; Villoria A; Carbajo AY; Lorente R; García-López S; Piqueras M; Hinojosa E; Arajol C; Sicilia B; Conesa AM; Sainz E; Almela P; Llaó J; Roncero O; Camo P; Taxonera C; Domselaar MV; Pajares R; Legido J; Madrigal R; Lucendo AJ; Alcaín G; Doménech E; Gisbert JP;
Aliment Pharmacol Ther; 2018 Oct; 48(8):839-851. PubMed ID: 30281832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
